A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA

INTRODUCTION: The SUSTAIN 3 and 7 clinical trials compared the efficacy and safety of once-weekly semaglutide relative to exenatide extended-release (ER) and dulaglutide, respectively, in the treatment of patients with type 2 diabetes (T2D). The trials included a series of clinically relevant single...

Descripción completa

Detalles Bibliográficos
Autores principales: Johansen, Pierre, Hunt, Barnaby, Iyer, Neeraj N., Dang-Tan, Tam, Pollock, Richard F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824375/
https://www.ncbi.nlm.nih.gov/pubmed/30875029
http://dx.doi.org/10.1007/s12325-019-00915-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824375/
https://www.ncbi.nlm.nih.gov/pubmed/30875029
http://dx.doi.org/10.1007/s12325-019-00915-8

Ejemplares similares